Project Grant HT9425261E134
- Federal Project Grant Award Summary Yale University received a $522,736 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026 through June 30, 2029. The award supports research titled "Harnessing Myeloid Cell Ontogeny to Prevent Melanoma Brain Metastasis," to be conducted at Yale's New Haven, Connecticut facility. Under this award, Yale will deliver hypothesis-driven biomedical research and...
- Federal Grant Award Summary Yale University received a $1.05M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support research on harnessing myeloid cell ontogeny to prevent melanoma brain metastasis. The award, dated July 1, 2026, will be performed at Yale's New Haven, Connecticut location through June 30, 2029. This three-year research initiative aligns with the DHA's broader portfolio of hypothesis-driven...
- Federal Grant Award Summary Yale University received a $559,992 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded July 1, 2026, with an ultimate completion date of June 30, 2028. The research project, titled "Biological Role and Therapeutic Targeting of HLA Class I Antigen Processing Machinery Dysregulation in Human Non-Small Cell Lung Cancer Brain Metastases," will be conducted at Yale's New Haven,...
- Federal Grant Award Summary Yale University received a $1.25 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026 through June 30, 2029. The grant supports research targeting KDM5 histone demethylases as a therapeutic approach to treat breast cancer. This research initiative aligns with the DHA's mission to transform healthcare for service members and the American public through innovative...
- Federal Grant Award Summary Yale University received a $670,917 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective June 15, 2025, through June 14, 2027. The award supports research titled "Exploiting METTL3 Inhibition-Induced Dysregulation of DNA Repair in the Treatment of Leukemia," conducted at Yale's Hamden, Connecticut location. This research project investigates novel therapeutic...
- Federal Project Grant Award Summary Yale University received a $1,009,054 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2025 through August 31, 2029. The award supports research focused on the discovery and therapeutic targeting of endogenous retroviruses in clear cell renal cell carcinoma. This biomedical research initiative addresses cancer treatment through investigation of endogenous...
- Federal Grant Award Summary Yale University received a $1.675 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 15, 2025 through August 14, 2029. The award funds research and development activities focused on drug discovery for dystonia and frontotemporal degeneration, two neurodegenerative conditions of significant medical concern. Research will be conducted at Yale's New Haven, Connecticut...
- The U.S. Defense Health Agency awarded a $1,213,276 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2023 through August 31, 2026, will fund research on the role of vascular mimicry in the outgrowth of dormant melanoma micrometastases. The goal of this research is to transform health care for Service Members and the American public through innovative and impactful medical research on solutions...
- Federal Grant Award Summary Yale University received a $1,004,472 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded on June 15, 2025, with a completion date of June 14, 2029. The project, titled "Mast Cell Therapy for Ovarian Cancer," is being conducted at Yale's Hamden, Connecticut facility. This award supports advanced biomedical research aimed at developing innovative therapeutic interventions for...
- Federal Grant Award Summary Yale University received a $1,005,000 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for a four-year research initiative focused on mast cell therapy for ovarian cancer. The award, effective June 15, 2025 through June 14, 2029, supports biomedical research aimed at developing novel therapeutic interventions to address cancer treatment challenges relevant to military service members and the...
Yale University received a $527,262 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026, through June 30, 2029. The award funds research titled "Harnessing Myeloid Cell Ontogeny to Prevent Melanoma Brain Metastasis," to be conducted at Yale's New Haven, Connecticut campus. This project represents a hypothesis-driven biomedical research initiative designed to investigate medical solutions aligned with military health priorities while advancing broader public health objectives. The grant supports basic and translational research activities focused on understanding myeloid cell development and its role in preventing melanoma metastasis to the brain. As part of the DHA's competitive research portfolio, the project underwent a two-tier review process evaluating technical merit and military relevance. Award recipients under this program typically deliver research and development services, including biomarker discovery, therapeutic development, and translational research activities addressing critical health challenges such as oncology and immunotherapy.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $527.3k | 4/29/26 |